指南与共识慢性肾脏病肾血管病与高血压

2型糖尿病合并慢性肾脏病的临床意义与管理指南

Clinical implications and guidelines for CKD in type 2 diabetes.
指南 / 共识 · Nephrol Dial Transplant · 2023-01-01

本文综述2型糖尿病(T2D)合并慢性肾脏病(CKD)的流行病学及指南制定过程,汇总近期指南推荐:所有指南均推荐每年筛查CKD、控制血压和血糖,统一推荐肾素-血管紧张素系统(RAS)抑制;所有指南推荐使用已证实获益的钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂;最新指南推荐非奈利酮。

要点

  • 所有现行指南推荐对T2D患者每年筛查CKD,并控制血压和血糖。
  • RAS抑制被统一推荐为一线治疗;SGLT2抑制剂获所有指南推荐。
  • 非奈利酮获最新指南推荐,系首个具有肾脏结局数据的非甾体类盐皮质激素受体拮抗剂。

核心结论

  • 现行指南继续推荐筛查CKD、以RAS抑制为一线治疗控制血压及控制血糖。
  • 基于稳健的临床试验数据,SGLT2抑制和非奈利酮是当前指南中改善T2D合并CKD结局的新增推荐。

研究设计与样本

  • 综述了T2D合并CKD的流行病学及指南制定过程,包括数据收集、分级和共识形成。
  • 报告了包含近期肾脏结局临床试验的最新CKD合并T2D管理指南及其支持证据。

主要发现

  • 所有现行指南推荐每年筛查CKD、控制血压和血糖,但目标水平和背景治疗推荐存在差异。
  • RAS抑制被统一推荐;所有指南推荐使用已证实获益的SGLT2抑制剂,对估算肾小球滤过率和白蛋白尿水平的建议略有差异。
  • 非奈利酮获最新版指南推荐。

关键数值与推荐

  • 所有现行指南推荐每年筛查CKD。
  • RAS抑制被统一推荐。
  • 所有指南推荐使用已证实获益的SGLT2抑制剂。
  • 最新指南推荐非奈利酮。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD) is a complication of type 2 diabetes (T2D) with high morbidity and mortality. The prevalence of CKD in T2D is increasing due to rising numbers of persons with T2D. Multiple clinical trials have been conducted testing novel therapies to reduce the progression of CKD, cardiovascular morbidity, in particular hospitalization for heart failure, and mortality. Results of these clinical trials have informed guidelines for the management of CKD in T2D. METHODS: The epidemiology of CKD in T2D and the process of guideline writing, including data gathering, grading and consensus development, were reviewed. Recent guidelines for the management of CKD in T2D that include recent renal outcome clinical trials are reported, along with supporting evidence. RESULTS: All current guidelines recommend annual screening for CKD, control of blood pressure and glucose, although the target levels and background therapy recommendations vary. Renin-angiotensin system (RAS) inhibition is uniformly recommended. Sodium-glucose cotransporter-2 (SGLT2) inhibition with proven agents is recommended by all guidelines, with minor variations in suggested estimated glomerular filtration rate and albuminuria levels. Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist with renal outcome data, is recommended by the most recent guideline available. CONCLUSIONS: Current guidelines continue to recommend screening for CKD, blood pressure control using RAS inhibition as first-line therapy, and glucose control. SGLT2 inhibition and finerenone are recent additions to current guidelines to improve CKD outcomes in T2D, based on robust clinical trial data.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhang RM, Persson F, McGill JB, et al. Clinical implications and guidelines for CKD in type 2 diabetes. Nephrol Dial Transplant. 2023. PMID: 36264310. doi:10.1093/ndt/gfac285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。